FDA Sends Warning Letter to Eden Over Compounded GLP-1 Labeling and "FDA-Licensed" Facility Claims
On June 8, 2026, FDA issued a warning letter to Eden Health International Inc. dba Eden after a March 2026 review of tryeden.com, which offers compounded semaglutide and tirzepatide products. FDA says compounded semaglutide and tirzepatide products pictured on the site identify "Eden" on the label, "suggesting Eden is the compounder of those drugs when in fact it is not," and that describing suppliers as "FDA-licensed 503(a) outsourcing facilities" is "false and misleading" because FDA does not license compounding facilities. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
Source: FDA original ↗